



---

National Association of State  
Controlled Substances Authorities

**NASCSA Resolution 2016-02**  
**October 2015**  
**New Orleans, Louisiana**

**A Resolution Encouraging States to Expediently Reschedule Any Food and Drug Administration-Approved Cannabidiol Product Following Rescheduling by the Drug Enforcement Administration**

**WHEREAS**, the United States Government has an established federal review process involving the Food and Drug Administration (FDA) for approving new medicines as safe and effective and making them available to patients who may benefit from them; and

**WHEREAS**, when the FDA reviews a New Drug Application and determines that a product or substance has a potential for abuse, FDA provides this information to the Drug Enforcement Administration (DEA) for scheduling or re-scheduling under the Comprehensive Drug Abuse Prevention and Control Act of 1970 (commonly known as the federal Controlled Substances Act); and

**WHEREAS**, all fifty State Governments, the District of Columbia and Puerto Rico have enacted and implemented Controlled Substances Acts which parallel the federal Controlled Substances Act; and

**WHEREAS**, products containing cannabidiol (CBD) are currently classified as Schedule I controlled substances under both federal and state law; and

**WHEREAS**, CBD is under development by the pharmaceutical industry and is showing promising therapeutic results, particularly in treating seizures associated with intractable epilepsy and other diseases in children and adults; and

**WHEREAS**, many patients with serious illnesses, and their families, are desperate to obtain some relief from their symptoms and have gone to extreme efforts to obtain unapproved drug substances, often without the knowledge and supervision of their specialist physician;

**WHEREAS**, such unapproved products have not been adequately analyzed or tested, may be contaminated, may not contain the ingredients or the quantity of ingredients listed on the label, and may be harmful to patients; and

**WHEREAS**, CBD products that have been approved by FDA and have been demonstrated to be safe and efficacious should be made available to patients , as soon as possible, following rescheduling by DEA;

**THEREFORE BE IT RESOLVED**, that the National Association of State Controlled Substances Authorities (NASCSA) encourages the states, the District of Columbia and Puerto Rico to approve and reschedule FDA-approved CBD products as expeditiously as possible following rescheduling by the DEA.

ATTEST: \_\_\_\_\_  
                    President

DATE: \_\_\_\_\_